Targeting Blood-Clotting Pathway Improves Mesothelioma Treatment

A team of researchers at the Cancer and Vascular Biology Research Center in Haifa, Israel, and the Langone Medical Center in New York collaborated on research of a common blood-clotting pathway. Targeting this pathway may offer a unique avenue for improving existing mesothelioma treatments. Researchers said the standard first-line chemotherapy for malignant pleural mesothelioma — a combination of Alimta (pemetrexed) and cisplatin — offers little benefit to most mesothelioma patients. “This treatment regimen confers a median progression-free survival of 5.7 months,” according to the study published December 2018 in Oncotarget. “No alternative can be offered when this treatment fails, thus underscoring the urgent needs for novel treatment modalities.” The focus on a blood-clotting pathway to target mesothelioma tumors has yielded promising early results. The findings point to the need for additional research and human clinical trials. Role of Natural and Synthetic Blood-Clotting Substances Heparin is a substance produced by the body. It prevents blood clots from forming in the wrong place at the wrong time. It can be given as a medication to prevent blood clots, too. Heparanase — the substance that breaks down heparin — promotes blood clot formation. Like heparin, the heparanase enzyme also is produced in the body and can be used as a drug to treat certain health conditions. In essence, these two substances work in opposition to...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

The National Institute for Occupational Safety and Health has launched the first nationwide Firefighter Cancer Registry, linking workplace exposures to deadly malignancies such as mesothelioma. Officials administering the study believe the registry will help reduce the incidence of various cancers for firefighters. “A national registry will go a long way toward answering the many questions still out there,” Dr. Kenny Fent, an industrial hygienist at NIOSH who is leading the effort, told The Mesothelioma Center at Asbestos.com. “We’re just laying the groundwork now, but in the long run, we want to h...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
(Natural News) Johnson &Johnson has been ordered to pay $29 million after a California jury determined that its baby powder contributed substantially to a woman’s mesothelioma. The immensely popular product, which has been widely used on babies and adults alike for decades, is the target of more than 13,000 similar lawsuits that have been...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Jury Awards $29.4 Million in Talcum Powder/Cancer Case A woman who said her mesothelioma was caused by her regular use of Johnson&...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
A woman who claims asbestos in Johnson &Johnson products caused her deadly cancer was awarded $29.4 million by a California jury on Wednesday, Reuters reports. A jury in a California Superior Court in Oakland determined that defective Baby Powder was a “substantial contributing factor” to Terry Leavitt’s mesothelioma, an aggressive cancer that affects the tissue that coats internal organs, the Associated Press reports. Leavitt said she often used two talcum-powder-based Johnson &Johnson products — Baby Powder and Shower to Shower powder — in the 1960s and 1970s, and claims they contrib...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer onetime Source Type: news
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Cancer incidence in an Austrian alpine valley 1983-2012 : A descriptive study. Wien Klin Wochenschr. 2019 Mar 14;: Authors: Hutter HP, Waldhoer T, Müller K, Hackl M, Weitensfelder L, Heinzl H Abstract After one of Austria's largest environmental scandals in 2014, which involved the release of hexachlorobenzene (HCB) in the Carinthian valley Görtschitztal, concerns about increased cancer rates have arísen in the affected local population. A descriptive study was conducted to examine the cancer incidence rates between 1983 and 2012. Data from the affected area (Görtschitz...
Source: Wiener Klinische Wochenschrift - Category: General Medicine Authors: Tags: Wien Klin Wochenschr Source Type: research
chel L O’Donnell Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 foci quantification, correlated with growth inhibition ex vivo induced by rucaparib (a PARPi) and 12-month survival following platinum chemotherapy. The aim of this study was to determine the feasibility of measuring HRR dysfunction (HRD) in other tumours, in order to estimate the frequency and hence wid...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 6 March 2019Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Marta Betti, Anna Aspesi, Marika Sculco, Giuseppe Matullo, Corrado Magnani, Irma DianzaniAbstractMalignant mesothelioma (MM) is an aggressive cancer associated with asbestos exposure. Studies of familial malignant pleural mesothelioma (MPM) have suggested the existence of a genetic predisposition. Information on the role of genetic risk factors in the development of MM has been growing in the last years, and both low- and high-risk genetic factors have been identified, but genetic factors alone (without any expos...
Source: Mutation Research Reviews in Mutation Research - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 4 March 2019Source: Pathology - Research and PracticeAuthor(s): Gamze Kulduk, Özgür Ekinci, Gizem Toker, Umut Demirci, Esra Özaydın, Nalan Akyürek, Leyla MemişAbstractMalignant mesothelioma (MM) is an aggressive cancer with a poor prognosis. The most common genetic alteration in MM is the deletion of the INK4a/ARF locus, which encodes the p16 protein and is located on the short arm of chromosome 9 (9p21). Recently, it has been shown that homozygous deletion of 9p21 has both diagnostic and prognostic significance in MM. It is a known fact that, to interpret fluorescen...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Alimta | Asbestosis | Biology | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Clinical Trials | Genetics | Israel Health | Laboratory Medicine | Mesothelioma | Middle East Health | Study | Transplants